Met Non Small Cell Cancer Registry (MOMENT) (NCT05376891)
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Who can join: Review the eligibility criteria below.
Location: Holy Cross Health — Fort Lauderdale, Florida
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (79 Sites)
Showing the first 25 of 79 sites.
- Holy Cross Health — Fort Lauderdale, Florida
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Vanderbilt University Medical Center — Nashville, Tennessee
- Klinikum Klagenfurt Am Woerthersee — Klagenfurt,
- Landeskrankenhaus Salzburg - Universitätsklinikum der PMU — Salzburg,
- Klinik Floridsdorf — Vienna,
- Jessa Ziekenhuis — Hasselt,
- AZ Delta — Roeselare,
- AZ Nikolaas — Sint-Niklaas,
- Cliniques UCL de Mont-Godinne (7077) — Yvoir,
- Ottawa Hospital General Campus — Ottawa,
- Centre Intégré de Cancérologie du CHU de Québec — Québec,
- Princess Margaret Cancer Centre — Toronto,
- British Columbia Cancer Agency (6864) — Vancouver,
- FN Olomouc — Olomouc,
- University Hospital Na Bulovce — Prague,
- Centre Hospitalier de Cholet — Cholet,
- CHRU Lille — Lille,
- Hôpital du Scorff — Lorient,
- Centre Leon Berard — Lyon,
- Groupe Hospitalier Paris Saint Joseph — Paris,
- Hospital Tenon & University Paris 6 — Paris,
- Institut Curie - Centre de Lutte Contre le Cancer (CLCC) — Paris,
- CHU de Pontchaillou — Rennes,
- CHU de Toulouse Hopital Larrey — Toulouse,
📞 Contact the Study Coordinator
Phone: (888) 275-7376
Email: eMediUSA@emdserono.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children — Rochester, Minnesota
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Aurora, Colorado
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training — Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain — Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors — Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer — Los Angeles, California
Explore by condition: All Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.